Glytr Therapeutics, Inc.
Irvine, CA Doing business as Glytr Therapeutics Inc.
- UEI
- ZKQLT6S8LXY9
- CAGE
- 7S8B8
- Primary NAICS
- Not on record
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 5151 California Ave #150, Irvine, CA 92617, USA
- Website
- glytrtherapeutics.com
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Maximizing glytr pan-cancer immunotherapy by enhancing target density - abstract BI-specific antibodies and chimeric… | National Cancer Institute | $463,510 | |
| Extended?half-life?GLYTR1 combined with checkpoint blockade?for cancer immunotherapy - abstract treatment of… | National Cancer Institute | $4,612,190 | |
| Cancer immunotherapy targeting TN antigen - abstract cancer immunotherapeutic BI-specific proteins and engineered… | National Cancer Institute | $1,194,534 | |
| O-glycan-dependent immunotherapy for cancer | National Cancer Institute | $300,614 |
About Glytr Therapeutics, Inc.
Glytr Therapeutics, Inc. is a for-profit corporate entity registered in SAM.gov since December 26, 2016, located in Irvine, California. The company appears to be focused on developing innovative cancer immunotherapies, specifically targeting tumor-associated carbohydrate antigens (TACAs) through a proprietary technology platform called Glycan-dependent T cell Recruiter (GLYTR). Their research concentrates on creating novel bi-specific antibodies and chimeric antigen receptor (CAR) T-cell products designed to selectively target and eliminate cancer cells while minimizing toxicity to normal tissues.
The company has been awarded multiple project grants from the National Cancer Institute (NCI) totaling over $900,000, with research periods spanning from 2021 to 2028. These federal grants support advanced cancer immunotherapy research, including developing extended half-life immunotherapeutic approaches and creating targeted therapies that can potentially address challenging solid tumors. Specifically, their grant-funded projects aim to maximize pan-cancer immunotherapy effectiveness by enhancing target density, combining GLYTR1 and GLYTR2 therapies, and metabolically increasing cancer antigen expression. The research focuses on innovative strategies like targeting β1,6GlcNAc-branched N-glycans and abnormal carbohydrate antigens such as the TN antigen, which are prevalent in various cancer types but have limited expression in normal tissues. These grants demonstrate Glytr Therapeutics' commitment to developing cutting-edge, potentially paradigm-shifting cancer treatment technologies through rigorous scientific research and development.
Quick answers
What is Glytr Therapeutics, Inc.'s UEI?
Glytr Therapeutics, Inc.'s Unique Entity ID (UEI) in SAM.gov is ZKQLT6S8LXY9.
What is Glytr Therapeutics, Inc.'s CAGE code?
Glytr Therapeutics, Inc.'s CAGE code is 7S8B8.
Where is Glytr Therapeutics, Inc. located?
Glytr Therapeutics, Inc.'s physical address in SAM.gov is 5151 California Ave #150, Irvine, CA 92617, USA.
Is Glytr Therapeutics, Inc. registered in SAM.gov?
Yes. Glytr Therapeutics, Inc.'s SAM.gov registration is active through December 26, 2026.
What is Glytr Therapeutics, Inc.'s most recent federal award?
Glytr Therapeutics, Inc.'s most recent federal grant award is Maximizing glytr pan-cancer immunotherapy by enhancing target density - abstract BI-specific antibodies and chimeric… (R42CA302415), from National Cancer Institute, on September 10, 2025.
On GovTribe
See Glytr Therapeutics, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors